The company continues to collect data and says it’s in discussions with the FDA regarding an expansion of its EUA to include this age group.
And the second reason is to be sure their teens reach full immunity before the new school year — or even before the start of summer activities.
More than 25 million Americans are between the ages of 12 and 17, according to Kids Count data.
We can imagine that a government may order a higher number of vaccine doses if that particular vaccine can be given to a broader population.
It seems likely the biotech company will bring its vaccine to teens before the start of the school year — meeting its original goal.
And Moderna may have to convince some governments that its vaccine soon may be given to teens.